How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
|Poll|September 14, 2016
Mini Quiz: ADHD Comorbidity
Author(s)W. Burleson Daviss, MD, Joseph B. Bond, MD
What are the facts regarding co-occurring depression and ADHD?
Advertisement
Which of the following is FALSE regarding co-occurring depression and ADHD?
Advertisement
Related to this article
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
Check out our pipeline updates from September!
Advertisement
Advertisement
Trending on Psychiatric Times
1
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
2
The New, Impending Adult ADHD Guidelines
3
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
4
Relief Is Not Free: A Case Study of Athlete Cannabis Use
5